

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



USA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/55, 15/85, 9/64, 5/10, A61K 38/48		A1	(11) International Publication Number: WO 99/20767 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/US98/22152			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 20 October 1998 (20.10.98)			
(30) Priority Data: 08/955,636 23 October 1997 (23.10.97) US			
(71) Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street, S.E., Minneapolis, MN 55455 (US).			
(72) Inventor: NELSESTUEN, Gary, L.; 1514 Fulham Street, St. Paul, MN 55108 (US).			Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(74) Agent: ELLINGER, Mark, S.; Fish & Richardson P.C., P.A., Suite 3300, 60 South Sixth Street, Minneapolis, MN 55402 (US).			

(54) Title: MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES

(57) Abstract

The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	CR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

- 1 -

MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES

Background of the Invention

5 Vitamin K-dependent proteins contain 9 to 13 gamma-carboxyglutamic acid residues (Gla) in their amino terminal 45 residues. The Gla residues are produced by enzymes in the liver that utilize vitamin K to carboxylate the side chains of glutamic acid residues in 10 protein precursors. Vitamin K-dependent proteins are involved in a number of biological processes, of which the most well-described is blood coagulation (reviewed in Furie, B. and Furie, B.C., 1988, Cell, 53:505-518). Vitamin K-dependent proteins include protein Z, protein 15 S, prothrombin, factor X, factor IX, protein C, factor VII and Gas6. The latter protein functions in cell growth regulation. Matsubara et al., 1996, Dev. Biol., 180:499-510. The Gla residues are needed for proper calcium binding and membrane interaction by these 20 proteins. The membrane contact site of factor X is thought to reside within amino acid residues 1-37. Evans and Nelsestuen, 1996, Protein Science 5:suppl. 1, 163 Abs. Although the Gla-containing regions of the plasma proteins show a high degree of sequence homology, they 25 have at least a 1000-fold range in membrane affinity. McDonald, J.F. et al., 1997, Biochemistry, 36:5120-5137.

Factor VII functions in the initial stage of blood clotting and may be a key element in forming blood clots. The inactive precursor, or zymogen, has low enzyme 30 activity that is greatly increased by proteolytic

- 2 -

cleavage to form factor VIIa. This activation can be catalyzed by factor Xa as well as by VIIa-tissue factor, an integral membrane protein found in a number of cell types. Fiore, M.M., et al., 1994, J. Biol. Chem., 269:143-149. Activation by VIIa-tissue factor is referred to as autoactivation. It is implicated in both the activation (formation of factor VIIa from factor VII) and the subsequent activity of factor VIIa. The most important pathway for activation *in vivo* is not known.

Factor VIIa can activate blood clotting factors IX and X. Tissue factor is expressed at high levels on the surface of some tumor cells. A role for tissue factor, and for factor VIIa, in tumor development and invasion of tissues is possible. Vrana, J.A. et al., Cancer Res., 56:5063-5070. Cell expression and action of tissue factor is also a major factor in toxic response to endotoxic shock. Dackiw, A.A. et al., 1996, Arch. Surg., 131:1273-1278.

Protein C is activated by thrombin in the presence of thrombomodulin, an integral membrane protein of endothelial cells. Esmon, N.L. et al., 1982, J. Biol. Chem., 257:859-864. Activated protein C (APC) degrades factors Va and VIIIa in combination with its cofactor, protein S. Resistance to APC is the most common form of inherited thrombosis disease. Dahlback, B., 1995, Blood, 85:607-614. Vitamin k inhibitors are commonly administered as a prophylaxis for thrombosis disease.

Vitamin k-dependent proteins are used to treat certain types of hemophilia. Hemophilia A is characterized by the absence of active factor VIII, factor VIIIa, or the presence of inhibitors to factor VIII. Hemophilia B is characterized by the absence of active factor IX, factor IXa. Factor VII deficiency, although rare, responds well to factor VII administration. Bauer, K.A., 1996, Haemostasis, 26:155-

- 3 -

158, suppl. 1. Factor VIII replacement therapy is limited due to development of high-titer inhibitory factor VIII antibodies in some patients. Alternatively, factor VIIa can be used in the treatment of hemophilia A
5 and B. Factor IXa and factor VIIa activate factor X. Factor VIIa eliminates the need for factors IX and VIII by activating factor X directly, and can overcome the problems of factor IX and VIII deficiencies with few immunological consequences. Hedner et al., 1993,
10 Transfus. Medi. Rev., 7:78-83; Nicolaisen, E.M. et al., 1996, Thromb. Haemost., 76:200-204. Effective levels of factor VIIa administration are often high (45 to 90 µg/kg of body weight) and administration may need to be repeated every few hours. Shulman, S. et al., 1996,
15 Thromb. Haemost., 75:432-436.

A soluble form of tissue factor (soluble tissue factor or sTF) that does not contain the membrane contact region, has been found to be efficacious in treatment of hemophilia when co-administered with factor VIIa. U.S.
20 Patent No. 5,504,064. In dogs, sTF was shown to reduce the amount of factor VIIa needed to treat hemophilia. Membrane association by sTF-VIIa is entirely dependent on the membrane contact site of factor VII. This contrasts to normal tissue-factor VIIa complex, which is bound to
25 the membrane through both tissue factor and VII(a).

Summary of the Invention

It has been discovered that modifications within the γ-carboxyglutamic acid (GLA) domain of vitamin K-dependent polypeptides enhance their membrane binding
30 affinities. Vitamin K-dependent polypeptides modified in such a manner have enhanced activity and may be used as anti-coagulants, pro-coagulants or for other functions that utilize vitamin k-dependent proteins. For example, an improved factor VII molecule may provide several

- 4 -

benefits by lowering the dosage of VIIa needed, the relative frequency of administration and/or by providing qualitative changes that allow more effective treatment of deficiency states.

5 The invention features vitamin k-dependent polypeptides that include a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain is from about amino
10 acid 1 to about amino acid 45 and includes at least one amino acid substitution. For example, the amino acid substitution can be at amino acid 11, 12, 29, 33 or 34. Preferably, the substitution is at amino acid 11, 33 or 34. The modified GLA domain may include an amino acid
15 sequence which, in the calcium saturated state, forms a tertiary structure having a cationic core with a halo of electronegative charge.

The vitamin k-dependent polypeptide may be, for example, protein C, activated protein C, factor IX,
20 factor IXa, factor VII, factor VIIa or active site modified factor VIIa. The modified GLA domain of protein C or activated protein C may include a glutamic acid residue at amino acid 33 and an aspartic acid residue at amino acid 34 (SEQ ID NO:19). The modified GLA domain of protein C or activated protein C may also include a glutamine or glutamic acid residue at amino acid 11 (SEQ ID NO:20 and SEQ ID NO:21, respectively). Additionally, a glycine residue may be substituted at amino acid 12 in the GLA domain of protein C or activated protein C (SEQ
25 ID NO:24 or SEQ ID NO:35). The modified GLA domain of factor VII, factor VIIa, and active site modified factor VIIa may contain a substitution at amino acid 11 and 33. For example, a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30) may
30 be substituted.
35

- 5 -

The invention also features an isolated nucleic acid encoding a vitamin K-dependent polypeptide. As used herein, the term isolated (purified) refers to a sequence corresponding to part or all of the gene encoding a 5 vitamin K-dependent polypeptide, but free of sequences that normally flank one or both sides of the gene in a mammalian genome. The vitamin K-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a 10 corresponding native vitamin K-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution.

The invention also features a mammalian host cell including a nucleic acid vector encoding a vitamin k-dependent polypeptide. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain includes at least one amino acid 20 substitution at, for example, amino acid 11, 12, 29, 33 or 34. The vitamin k-dependent polypeptide may be, for example, factor VII or factor VIIa and include an amino acid substitution at amino acid 11 and amino acid 33. For example, the amino acid substitution can include a 25 glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

The invention also relates to a pharmaceutical composition that includes a pharmaceutically acceptable carrier and an amount of a vitamin k-dependent 30 polypeptide effective to inhibit clot formation in a mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA 35 domain includes at least one amino acid substitution.

- 6 -

The vitamin k-dependent polypeptide may be, for example, protein C, activated protein C or active site modified factor VIIa. Protein C or Activated Protein C can include, for example, a glutamic acid residue at amino acid 33 and an aspartic acid residue at amino acid 34 (SEQ ID NO:19). Protein C or Activated Protein C can further include, a glutamine at amino acid 11 (SEQ ID NO:20) or a glutamic acid at amino acid 11 (SEQ ID NO:21). The amino acid substitution also can include a glycine at amino acid 12 (SEQ ID NO:24 or SEQ ID NO:35). Active-site modified Factor VIIa can include, for example, a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

The invention also features a pharmaceutical composition that includes a pharmaceutically acceptable carrier and an amount of a vitamin k-dependent polypeptide effective to increase clot formation in a mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. The vitamin k-dependent polypeptide may be, for example, factor VII, factor VIIa, factor IX or factor IXa. The pharmaceutical composition may also include soluble tissue factor. Factor VII or Factor VIIa can include an amino acid substitution at amino acid 11 and amino acid 33. For example, a glutamine residue can be substituted at amino acid 11 and a glutamic acid residue can be substituted at amino acid 33 (SEQ ID NO:30).

A vitamin K-dependent polypeptide for use in treating a clotting disorder is also described. The vitamin K-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin K-

- 7 -

dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. Useful modified vitamin K-dependent polypeptides include, for example, protein C, activated protein C, factor VII, factor VIIa, 5 active-site modified factor VIIa, factor IX, and factor IXa as described above.

The invention also features the use of a vitamin K-dependent polypeptide in the manufacture of a medicament for the treatment of a clotting disorder. The 10 vitamin K-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin K-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. Useful modified 15 vitamin K-dependent polypeptides include, for example, protein C, activated protein C, factor VII, factor VIIa, active-site modified factor VIIa, factor IX, and factor IXa as described above.

A method of decreasing clot formation in a mammal 20 is also described. The method includes administering an amount of a vitamin k-dependent polypeptide effective to decrease clot formation in the mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide 25 relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. The vitamin k-dependent polypeptide may be, for example, protein C, activated protein C or active site modified factor VIIa. Protein C 30 or Activated protein C can include a glutamic acid residue at amino acid 33 and an aspartic acid residue at amino acid 34 (SEQ ID NO:19). A glutamine or glutamic acid can be further substituted in protein C or Activated protein C (SEQ ID NO:20 or SEQ ID NO:21, respectively). A 35 glycine can be further substituted at amino acid 12 (SEQ

- 8 -

ID NO:24 or NO:35). Active-site modified Factor VIIa can include a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

The invention also features a method of increasing 5 clot formation in a mammal. The method includes administering an amount of a vitamin k-dependent polypeptide effective to increase clot formation in the mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding 10 affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. The vitamin k-dependent polypeptide may be, for example, factor VII, factor VIIa, factor IX or factor IXa. Factor 15 VII or Factor VIIa can include an amino acid substitution at amino acid 11 and at amino acid 33. For example, the amino acid substitution can include a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

20 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein 25 can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present 30 specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, 35 and from the claims.

- 9 -

Brief Description of the Drawings

The amino acid sequences of the GLA domain of wild type VIIa and VIIQ11E33 are found in SEQ ID NO:3 and SEQ ID NO:30, respectively. The amino acid sequences of the 5 GLA domain of bovine factor X, bovine protein C, human protein C and bovine protein C-H11 are found in SEQ ID NO:18, SEQ ID NO:2, SEQ ID NO:1 and SEQ ID NO:23, respectively. The amino acid sequence of the GLA domain of protein C VQ33E,N34D is found in SEQ ID NO:19.

10 Figure 1 depicts the binding, with standard deviations, of wild type VIIa (open circles), VIIQ11E33 (filled circles), and bovine factor X (filled triangles) to membranes.

Figure 2 depicts the autoactivation of VIIQ11E33.

15 The dashed line shows activity in the absence of phospholipid.

Figure 3 depicts the activation of factor X by factor VIIa. Results for wild type factor VIIa (open circles) and VIIaQ11E33 (filled circles) are given for a 20 concentration of 0.06 nM.

Figure 4 depicts the coagulation of human plasma by VIIa and VIIaQ11E33 with soluble tissue factor.

Figure 5 depicts the coagulation of plasma by factor VII zymogens and normal tissue factor.

25 Figure 6 depicts the inhibition of clot formation by active-site modified factor VIIaQ11E33 (DEGR-VIIaQ11E33).

Figure 7 depicts the circulatory time of factor VIIQ11E33 in rats.

30 Figure 8 depicts the membrane interaction by normal and modified proteins. Panel A shows the interaction of wild type bovine protein C (open circles) and bovine protein C-H11 (filled circles) with vesicles. Panel B shows the interaction of wild type human protein 35 C (open circles) and human protein C-P11 (filled circles)

- 10 -

with membranes. In both cases, the dashed line indicates the result if all of the added protein were bound to the membrane.

Figure 9 depicts the influence of activated 5 protein C on clotting times. In panel A, the average and standard deviation for three determinations of clotting times for bovine plasma are shown for wild type bovine APC (open circles) and for bAPC-H11 (filled circles). In panel B, the average and standard deviation of three 10 replicates of human plasma coagulation for the wild type human (open circles) and human APC-P11 (filled circles) are shown.

Figure 10 depicts the inactivation of factor Va by bovine and human APC. Panel A depicts the inactivation 15 of factor Va by wild type bovine APC (open circles) and bovine APC-H11 (filled circles). Panel B depicts the inactivation of human factor Va in protein S-deficient plasma by either wild type human APC (open circles) and human APC-H11 (filled circles).

20 Figure 11 depicts the electrostatic distribution of protein Z. Vertical lines denote electropositive regions and horizontal lines denote electronegative regions

Figure 12 depicts the membrane binding and 25 activity of various protein Cs. Panel A shows membrane binding by wild type protein C (open circles), the P11H mutant of protein C (filled squares), Q33E,N34D mutant (filled circles) and bovine prothrombin (open squares). Panel B shows inhibition of blood coagulation by these 30 mutants. Panel C shows the inactivation of factor Va.

Figure 13 compares membrane binding and activity of human protein C mutants. Panel A compares the membrane binding of wild-type (open circles), E33 (open triangles) and E33D34 (filled circles). Panel B compares

- 11 -

the coagulation times using wild-type (open triangles), E33 (open circles) and E33D34 (filled circles).

Figure 14 compares membrane binding (Panel A) and coagulation inhibition (Panel B) with wild-type (open squares), H11 (filled circles), E33D34 (open triangles) and the triple H11E33D34 mutant (open circles) of bovine protein C.

Figure 15 depicts the membrane interaction properties of different vitamin K-dependent proteins.

10 Panel A compares membrane interaction of human (filled circles) and bovine (open circles) factor X. Panel B shows membrane interaction by normal bovine prothrombin fragment 1 (open circles), fragment 1 modified with TNBS in the absence of calcium (filled circles) and fragment 1
15 modified with TNBS in the presence of 25 mM calcium (filled squares). Panel C shows the rate of protein Z binding to vesicles at pH 9 (filled circles) and 7.5 (open circles).

Detailed Description

20 In one aspect, the invention features a vitamin k-dependent polypeptide including a modified GLA domain with enhanced membrane binding affinity relative to a corresponding native vitamin k-dependent polypeptide. Vitamin k-dependent polypeptides are a group of proteins
25 that utilize vitamin k in their biosynthetic pathway to carboxylate the side chains of glutamic acid residues in protein precursors. The GLA domain contains 9-13 γ -carboxyglutamic acid residues in the N-terminal region of the polypeptide, typically from amino acid 1 to about
30 amino acid 45. Protein Z, protein S, factor X, factor II (prothrombin), factor IX, protein C, factor VII and Gas6 are examples of vitamin k-dependent polypeptides. Amino acid positions of the polypeptides discussed herein are numbered according to factor IX. Protein S, protein C,
35 factor X, factor VII and human prothrombin all have one

- 12 -

less amino acid (position 4) and must be adjusted accordingly. For example, actual position 10 of bovine protein C is a proline, but is numbered herein as amino acid 11 for ease of comparison throughout. As used 5 herein, the term "polypeptide" is any chain of amino acids, regardless of length or post-translational modification. Amino acids have been designated herein by standard three letter and one letter abbreviations.

Modifications of the GLA domain include at least 10 one amino acid substitution. The substitutions may be conservative or non-conservative. Conservative amino acid substitutions replace an amino acid with an amino acid of the same class, whereas non-conservative amino acid substitutions replace an amino acid with an amino acid of a different class. Non-conservative 15 substitutions may result in a substantial change in the hydrophobicity of the polypeptide or in the bulk of a residue side chain. In addition, non-conservative substitutions may make a substantial change in the charge 20 of the polypeptide, such as reducing electropositive charges or introducing electronegative charges. Examples of non-conservative substitutions include a basic amino acid for a non-polar amino acid, or a polar amino acid for an acidic amino acid. The amino acid substitution 25 may be at amino acid 11, 12, 29, 33 or 34. Preferably, the amino acid substitution is at amino acid 11, 33 or 34. The modified GLA domain may include an amino acid sequence which, in the calcium saturated state, contributes to formation of a tertiary structure having a 30 cationic core with a halo of electronegative charge. Without being bound by a particular theory, enhanced membrane affinity may result from a particular electrostatic pattern consisting of an electropositive core completely surrounded by an electronegative surface.

- 13 -

Many vitamin K-dependent polypeptides are substrates for membrane-bound enzymes. Since no vitamin K-dependent polypeptides display the maximum potential membrane-binding affinity of a GLA domain, all must 5 contain amino acids whose purpose is to reduce binding affinity. Consequently, many vitamin K-dependent polypeptides contain amino acids that are non-optimal from the standpoint of maximum affinity. These residues effectively disrupt the binding site to provide a more 10 rapid turnover for an enzymatic reaction.

Lowered membrane affinity may serve several purposes. High affinity is accompanied by slow exchange, which may limit reaction rates. For example, when the prothrombinase enzyme is assembled on membranes with high 15 affinity for substrate, protein exchange from the membrane, rather than enzyme catalysis, is the limiting. Lu, Y. and Nelsestuen, G.L., 1996, Biochemistry, 35:8201-8209. Alternatively, adjustment of membrane affinity by substitution with non-optimum amino acids may balance the 20 competing processes of procoagulation (factor X, IX, VII and prothrombin) and anticoagulation (protein C, S). Although membrane affinities of native proteins may be optimal for normal states, enhancement of membrane affinity can produce proteins that are useful for *in* 25 *vitro* study as well as improved therapeutics for regulating blood clotting in pathological conditions *in vivo*.

Various examples of GLA domain modified vitamin k-dependent polypeptides are described below.

30 The vitamin k-dependent polypeptide may be protein C or activated protein C (APC). Amino acid sequences of the wild-type human (hC) and bovine (bC) protein C GLA domain are shown in Table 1. X is a Gla or Glu residue. In general, a protein with neutral (e.g., Q) or anionic

- 14 -

residues (e.g., D,E) at positions 11, 33 and 34 will have higher membrane affinity.

TABLE 1

hc: ANS-FLXXLRH₁,SSLXRXCIXX₂₁,ICDFXXAKXI₃₁,FQNVDDTLAF₄₁WSKH (SEQ ID NO:1)

5 **bc:** ANS-FLXXLRP₁,GNVXRCSXX₂₁,VCXFXXARXI₃₁,FQNTXDTMAF₄₁WSFY (SEQ ID NO:2)

The modified GLA domain of protein C or APC may include, for example, a glutamic acid residue at amino acid 33 and an aspartic acid residue at amino acid 34 (SEQ ID NO:19). The glutamic acid at position 33 may be further modified to γ -carboxyglutamic acid *in vivo*. For optimum activity, the modified GLA domain may include an additional substitution at amino acid 11. For example, a glutamine residue may be substituted at amino acid 11 (SEQ ID NO:20) or alternatively, a glutamic acid or an aspartic acid residue (SEQ ID NO:21 and SEQ ID NO:22, respectively) may be substituted. A histidine residue may be substituted at amino acid 11 in bovine protein C (SEQ ID NO:23). A further modification can include a substitution at amino acid 12 of a glycine residue for serine (SEQ ID NO:24 and SEQ ID NO:35). Replacement of amino acid 29 by phenylalanine, the amino acid found in prothrombin, is another useful modification (SEQ ID NO:25). Modified protein C with enhanced membrane binding affinity may be used in place of other injectable anticoagulants such as heparin. Heparin is typically used in most types of surgery, but suffers from a low efficacy/toxicity ratio. In addition, modified protein C with enhanced membrane affinity may be used in place of oral anticoagulants in the coumarin family, such as warfarin.

These modifications can also be made with active site modified APC. The active site of APC may be inactivated chemically, for example, by N-dansyl-glutamyl-glycylarginylchloromethylketone (DEGR) or by site-

- 15 -

directed mutagenesis of the active site. Sorensen, B.B. et al., 1997, J. Biol. Chem., 272:11863-11868. Active site-modified APC functions as an inhibitor of the prothrombinase complex. Enhanced membrane affinity of 5 active site modified APC may result in a more therapeutically effective polypeptide.

The vitamin k-dependent polypeptide may be factor VII or the active form of factor VII, factor VIIa. Native or naturally-occurring factor VII polypeptide has 10 low affinity for membranes. Amino acid sequences of the wild-type human (hVII) and bovine (bVII) factor VII GLA domain are shown in Table 2.

TABLE 2

hVII: ANA-FLXXLRP₁,GSLRXCKXX₂,QCSFXXARXI₃,FKDAXRTKLF₄,WISY (SEQ ID NO:3)

15 bVII: ANG-FLXXLRP₁,GSLRXCRXX₂,LCSFXXAHXI₃,FRNXXRTRQF₄,WVSY (SEQ ID NO:4)

The modified GLA domain of factor VII or factor VIIa may include, for example, a glutamic acid or aspartic acid residue at amino acid 11 (SEQ ID NO:26 and SEQ ID NO:27, respectively), a phenylalanine residue at 20 amino acid 29 (SEQ ID NO:28), or an aspartic acid residue at amino acid 33 (SEQ ID NO:29). Preferably, the GLA domain of factor VII or factor VIIa may include a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30). Vitamin k-dependent polypeptide modified in this manner has a much higher affinity for membranes than the native or wild type polypeptide. It also has a much higher activity in autoactivation, in factor Xa generation and in several blood clotting assays. Activity is particularly enhanced 25 at marginal coagulation conditions, such as low levels of tissue factor and/or phospholipid. For example, modified factor VII is about 4 times as effective as native VIIa 30 at optimum thromboplastin levels, but is about 20-fold as

- 16 -

effective at 1% of optimum thromboplastin levels. Marginal pro-coagulation signals are probably most predominant *in vivo*. Presently available clotting assays that use optimum levels of thromboplastin cannot detect 5 clotting time differences between normal plasma and those from hemophilia patients. Clotting differences between such samples are only detected when non-optimal levels of thromboplastin or dilute thromboplastin are used in clotting assays.

10 Another example of a vitamin k-dependent polypeptide is active-site modified Factor VIIa. The active site of factor VIIa may be modified chemically, for example, by DEGR or by site-directed mutagenesis of the active site. DEGR-modified factor VII is an 15 effective inhibitor of coagulation by several routes of administration. Arnljots, B. et al., 1997, J. Vasc. Surg., 25:341-346. Modifications of the GLA domain may make active-site modified Factor VIIa more efficacious due to higher membrane affinity. The modified GLA domain 20 of active-site modified Factor VIIa may include, for example, a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30). The vitamin K-dependent polypeptide may also be Factor IX or the active form of Factor IX, Factor IXa. 25 As with active site-modified factor VIIa, active site modified IXa and Xa may be inhibitors of coagulation. Amino acid sequences of the wild-type human (hIX) and bovine (bIX) factor IX GLA domain are shown in Table 3. For example, an aspartic acid or glutamic acid residue 30 may be substituted at amino acid 11 (SEQ ID NO:31 and SEQ ID NO:32, respectively), a phenylalanine residue at amino acid 29 (SEQ ID NO:33), or an aspartic acid residue at amino acid 34 (SEQ ID NO:34).

- 17 -

TABLE 3

hIX: YNSGKLXXFVQ₁,GNLXRXCMXX₂,KCSFXXARXV₃,FXNTXRTTXF₄,WKQY (SEQ ID NO:5)

bIX: YNSGKLXXFVQ₁,GNLXRXCMXX₂,KCSFXXARXV₃,FXNTXKRTTXF₄,WKQY (SEQ ID NO:6)

In another aspect, the invention features a
5 mammalian host cell including a vitamin k-dependent
polypeptide having a modified GLA domain that enhances
membrane binding affinity of the polypeptide relative to
a corresponding native vitamin k-dependent polypeptide.
The modified GLA domain includes at least one amino acid
10 substitution as discussed above. The mammalian host cell
may include, for example, modified factor VII or modified
factor VIIa. The GLA domain of modified factor VII or
modified factor VIIa may contain an amino acid
substitution at amino acid 11 and at amino acid 33.
15 Preferably, the amino acid substitution includes a
glutamine residue at amino acid 11 and a glutamic acid
residue at amino acid 33 (SEQ ID NO:30).

Suitable mammalian host cells are able to modify
vitamin k-dependent polypeptide glutamate residues to γ -
20 carboxyglutamate. Mammalian cells derived from kidney
and liver are especially useful as host cells.

The invention also features a pharmaceutical
composition including a pharmaceutically acceptable
carrier and an amount of a vitamin k-dependent
25 polypeptide effective to inhibit clot formation in a
mammal. The vitamin k-dependent polypeptide includes a
modified GLA domain with at least one amino acid
substitution that enhances membrane binding affinity of
the polypeptide relative to a corresponding native
30 vitamin k-dependent polypeptide. Useful modified vitamin
k-dependent polypeptides of the pharmaceutical
compositions can include, without limitation, protein C
or APC, active-site modified APC, active-site modified

- 18 -

factor VIIa, active-site modified factor IXa and active-site modified factor Xa as discussed above.

The concentration of a vitamin k-dependent polypeptide effective to inhibit clot formation in a mammal may vary, depending on a number of factors, including the preferred dosage of the compound to be administered, the chemical characteristics of the compounds employed, the formulation of the compound excipients and the route of administration. The optimal dosage of a pharmaceutical composition to be administered may also depend on such variables as the overall health status of the particular patient and the relative biological efficacy of the compound selected. These pharmaceutical compositions may be used to regulate coagulation *in vivo*. For example, the compositions may be used generally for the treatment of thrombosis. Altering only a few amino acid residues of the polypeptide as described above, generally does not significantly affect the antigenicity of the mutant polypeptides.

Vitamin k-dependent polypeptides that include modified GLA domains may be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable non-toxic excipients or carriers. Such compounds and compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions in aqueous physiological buffer solutions; for oral administration, particularly in the form of tablets or capsules; or for intranasal administration, particularly in the form of powders, nasal drops, or aerosols. Compositions for other routes of administration may be prepared as desired using standard methods.

Formulations for parenteral administration may contain as common excipients sterile water or saline,

- 19 -

polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or

5 polyoxethylene-polyoxypropylene copolymers are examples of excipients for controlling the release of a compound of the invention *in vivo*. Other suitable parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems,

10 and liposomes. Formulations for inhalation administration may contain excipients such as lactose, if desired. Inhalation formulations may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or they may

15 be oily solutions for administration in the form of nasal drops. If desired, the compounds can be formulated as gels to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration

20 In an alternative embodiment, the invention also features a pharmaceutical composition including a pharmaceutically acceptable carrier and an amount of a vitamin k-dependent polypeptide effective to increase clot formation in a mammal. The vitamin k-dependent

25 polypeptide includes a modified GLA domain with at least one amino acid substitution that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. These pharmaceutical compositions may be useful for the

30 treatment of clotting disorders such as hemophilia A, hemophilia B and liver disease.

In this embodiment, useful vitamin k-dependent polypeptides of the pharmaceutical compositions can include, without limitations, Factor VII or the active

35 form of Factor VII, Factor VIIa. The modified GLA domain

- 20 -

of Factor VII or Factor VIIa may include substitutions at amino acid 11 and amino acid 33, for example, a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30). The pharmaceutical 5 composition may further comprise soluble tissue factor. Factor VII is especially critical to blood coagulation because of its location at the initiation of the clotting cascade, and its ability to activate two proteins, factors IX and X. Direct activation of factor X by 10 factor VIIa is important for possible treatment of the major forms of hemophilia, types A and B, since the steps involving factors IX and VIII are bypassed entirely. Administration of factor VII to patients has been found to be efficacious for treatment of some forms of 15 hemophilia. Improvement of the membrane affinity of factor VII or VIIa by modification of the GLA domain provides the potential to make the polypeptide more responsive to many coagulation conditions, to lower the dosages of VII/VIIa needed, to extend the intervals at 20 which factor VII/VIIa must be administered, and to provide additional qualitative changes that result in more effective treatment. Overall, improvement of the membrane contact site of factor VII may increase both its activation rate as well as improve the activity of factor 25 VIIa on factor X or IX. These steps may have a multiplicative effect on overall blood clotting rates in vivo, resulting in a very potent factor VIIa for superior treatment of several blood clotting disorders.

Other useful vitamin k-dependent polypeptides for 30 increasing clot formation include Factor IX and Factor IXa.

In another aspect, methods for decreasing clot formation in a mammal are described. The method includes administering an amount of vitamin k-dependent 35 polypeptide effective to decrease clot formation in the

- 21 -

mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA 5 domain includes at least one amino acid substitution. Modified protein C or APC or modified active-site blocked factors VIIa, IXa, Xa and APC may be used for this method.

In another aspect, the invention also features 10 methods for increasing clot formation in a mammal that includes administering an amount of vitamin k-dependent polypeptide effective to increase clot formation in the mammal. The vitamin k-dependent polypeptide includes a modified GLA domain that enhances membrane binding 15 affinity of the polypeptide relative to a corresponding native vitamin k-dependent polypeptide. The modified GLA domain includes at least one amino acid substitution. Modified factor VII or VIIa and modified factor IX or IXa may be used in this method.

20 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

Examples

Example 1 - Factor VII with Enhanced Membrane Affinity
25 and Activity: It has been found that the membrane binding affinity of human blood clotting factor VII can be increased by site-directed mutagenesis. The properties of a P11Q,K33E mutant (referred to herein as Factor VIIQ11E33 or mutant factor VII (SEQ ID NO:30)) 30 have been characterized. Membrane affinity was increased over wild type protein by about 20-fold. Autoactivation by the mutant was increased by at least 100-fold over that of wild type factor VII. The activated form of VIIQ11E33 (referred to as VIIaQ11E33) displayed about 10-

- 22 -

fold higher activity toward factor X. The coagulation activity of VIIaQ11E33 with soluble tissue factor in normal plasma was about 10-fold higher than that of wild type VIIa. Coagulation activity of the zymogen,
5 VIIQ11E33, with normal tissue factor (supplied as a 1:100 dilution of thromboplastin-HS), was 20-fold higher than wild type Factor VII. The degree to which activity was enhanced was dependent on conditions, with VIIQ11E33 being especially active under conditions of low
10 coagulation stimuli.

In general, protein concentrations were determined by the Bradford assay using bovine serum albumin as the standard. Bradford, M.M., 1976, Analyt. Biochem. 248-254. Molar concentrations were obtained from the
15 molecular weights of 50,000 for factor VII and 55,000 for factor X. Unless indicated, all activity measurements were conducted in standard buffer (0.05 M Tris, pH 7.5, 100 mM NaCl).

Production of Mutant Factor VII: Mutant factor
20 VII was generated from wild type factor VII cDNA (GenBank Accession number M13232, NID g182799). Petersen et al., 1990, Biochemistry 29:3451-3457. The P11Q mutation (change of amino acid 11 from a proline residue to a glutamine residue) and the K33E mutation (change of amino
25 acid 33 from a lysine residue to a glutamic acid residue) were introduced into the wild type factor VII cDNA by a polymerase chain reaction strategy essentially as described by Vallette et al., 1989, Nucleic Acids Res. 17:723-733. During this process, a mutation-diagnostic
30 XmaIII restriction enzyme site was eliminated. Four PCR primers were designed to prime synthesis of two mutant fragments of M13232, one from MluI to BglII, positions 221 to 301, and the other from BglII to SstII, positions 302 to 787. These primers were used under standard PCR
35 cycling conditions (GENEAMP, Perkin Elmer) to prime

- 23 -

fragment synthesis using 1 ng of the wild-type factor VII cDNA as template. The resulting fragments were gel purified and digested with *Mlu*I and *Bgl*II or *Bgl*II and *Sst*II. The two purified fragments were then ligated into 5 the factor VIII cDNA in the expression vector Zem219b from which the corresponding wild-type sequence had been removed as a *Mlu*I-*Sst*II fragment. Petersen et al., 1990 *supra*. The mutated fragments were sequenced in their entirety to confirm the P11Q and K33E substitutions, as 10 well as to eliminate the possibility of other PCR-induced sequence changes.

Transfection, Selection and Purification: Baby hamster kidney (BHK) cells were grown in Dubeccos modified Eagles medium supplemented with 10% fetal calf 15 serum and penicillin-streptomycin. Subconfluent cells were transfected with the factor VII expression plasmid using lipofectAMINE (Gibco BRL) according to the manufacturers recommendations. Two days post-transfection, cells were trypsinized and diluted to 20 selective medium containing 1 μ M methotrexate (MTX). Stably-transfected BHK cells were subsequently cultured in serum-free Dubeccos modified Eagles medium supplemented with penicillin-streptomycin, 5 μ g/mL vitamin K₁ and 1 μ M MTX, and conditioned medium was 25 collected. The conditioned medium was applied twice to an immunoaffinity column composed of a calcium-dependent monoclonal antibody (CaFVII22) coupled to Affi-Gel 10. Nakagaki et al., 1991, Biochemistry, 30:10819-10824. The final purified Factor VIIQ11E33 ran as a single band on 30 SDS polyacrylamide gel electrophoresis, with no evidence of factor VIIa in the preparation. The pure VII(P11Q,K33E) mutant showed 1400-2800 factor VII units/mg.

Activation of Factor VII: Activated Factor 35 VIIaQ11E33 was formed by bovine factor Xa cleavage of

- 24 -

VIIQ11E33 (1:100 weight ratio, incubation for 1 hr at 37°C). Alternatively, Factor VIIaQ11E33 was obtained by autoactivation (37°C, 20 min) in a mixture containing 7 µM VIIQ11E33, 0.7 µM sTF and phospholipid
5 (phosphatidylserine / phosphatidylcholine (PS/PC), 25/75, 0.1 g/g protein).

Wild-type factor VIIa was a homogeneous, recombinant protein (NOVO Nordisk). Two preparations consisted of a commercial, lyophilized product and non-
10 lyophilized product. The latter protein was further purified on FPLC mono-Q and showed a specific activity of 80,000 units/mg, calibrated with a George King NPP standard.

Enhanced membrane interaction by Factor VIIQ11E33:

15 Phospholipid preparation, assay and measurement of protein-membrane binding was conducted by the method described by Nelsetuen and Lim, 1977, Biochemistry, 30:10819-10824. Large unilamellar vesicles (LUVs) and small unilamellar vesicles (SUVs) were prepared by
20 methods described previously. Hope, M.J., et al., Biochem. Biophys. Acta., 812:55-65; Huang, C., 1969, Biochemistry, 8:344-352. Highly pure phosphatidylserine (bovine brain) and egg phosphatidylcholine (Sigma Chemical Co.) were mixed in chloroform. The solvent was
25 removed by a stream of nitrogen gas. The dried phospholipids were suspended in buffer. SUVs were formed by sonication and gel filtration while LUVs were formed by freeze-thaw and extrusion. Phospholipid concentrations were determined by organic phosphate assay
30 assuming a phosphorous:phospholipid weight ratio of 25.

SUVS of either PS/PC (25/75) or PS/PC (10/90) were prepared. Protein was added to phospholipid at the weight ratios shown in Figure 1. Protein-membrane binding was assayed by light scattering at 90° by the
35 method of Nelsetuen and Lim, 1977 *supra*. Briefly, the

- 25 -

light scattering intensity of phospholipid vesicles alone (I_1) and after addition of protein (I_2) were measured and corrected for background from buffer and unbound protein. The molecular weight ratio of the protein-vesicle complex 5 (M_2) to that of the vesicles alone (M_1), can be estimated from the relationship in equation 1, where $\delta n/\delta c$ is the refractive index of the respective species.

$$I_2/I_1 = (M_2/M_1)^2 (\delta n/\delta c_2 / \delta n/\delta c_1)^2 \quad (\text{eq. 1})$$

If phospholipid and protein concentrations are known, the 10 concentration of bound [$P*PL$] and free protein [P] can be estimated. These values, together with the maximum protein binding capacity [$P*PL_{\max}$] of the vesicles (assumed to be 1.0 g/g for all proteins) can be used to obtain the equilibrium constant for protein-membrane 15 interaction by the relationship in equation 2, where all concentrations are expressed as molar protein or protein binding sites.

$$K_d = [P] [P*PL_{\max} - P*PL] / [P*PL] \quad (\text{eq. 2})$$

Binding was assessed at 5 mM calcium and is expressed as 20 the ratio, M_2/M_1 .

Figure 1 shows the binding of wild type VIIa (open circles) and factor VIIQ11E33 (filled circles) to membranes of either PS/PC=25/75, 25 $\mu\text{g}/\text{ml}$ (Figure 1A) or PS/PC=10/90, 25 $\mu\text{g}/\text{ml}$ (Figure 1B). VIIQ11E33 had much 25 higher affinity than wild type protein. Binding to PS/PC (25/75) was at the quantitative level so that [Protein_{free}] was essentially zero. Consequently, Kd values could not be estimated from this data. Membrane binding of bovine factor X (filled triangles) is shown in Figure 1 as a 30 reference. Bovine factor X is one of the highest affinity proteins in this family, giving a Kd for PS/PC (20/80) at 2 mM calcium of 40 nM. McDonald et al., 1997,

- 26 -

Biochemistry, 36:5120-5127. The Kd for bovine factor X, obtained from the result at a protein/phospholipid ratio of 0.55 (Figure 1), was 0.025 μ M.

Binding of wild-type and mutant Factor VII to membranes of PS/PC (10/90) was also determined (Figure 1B). The VIIQ11E33 bound at less than the quantitative level, which allowed a binding constant to be estimated from the relationship in equation 3.

$$K_d = [Protein_{free}] [Binding\ sites_{free}] / [Protein_{bound}] \quad (\text{eq. 3})$$

[Binding sites_{free}] were estimated from equation 4, assuming a maximum M2/M1 of 1.0 (i. e., [Binding sites_{total}] = [Phospholipid_{weight conc.}/Protein_{MW}]). This is a common value observed for several proteins of this family. See McDonald et al., 1997, *supra*.

15 [Binding sites_{free}] = [Binding sites_{total}] - [Protein_{bound}] (eq. 4)

Using these assumptions and the data at a protein to phospholipid ratio of 0.37, Kd values were 0.7 μ M for bovine factor X, 5.5 μ M for wild type factor VII and 0.23 μ M for VIIQ11E33. Thus, it was clear that factor 20 VIIQ11E33 was greatly improved in membrane binding affinity over wild type factor VII and had one of the highest membrane-binding affinities among the vitamin K-dependent proteins.

Enhanced activation of factor VIIQ11E33: The first step in coagulation involves the activation of factor VII. Autoactivation of VII was conducted in a solution containing 100 nM sTF (highly purified recombinant product from Dr. Walter Kisiel, Fiore et al., 1994, J. Biol. Chem., 269:143-149), 36 nM VIIQ11E33 and 30 PS/PC (25/75, 22 μ g/mL). Activity of VIIaQ11E33 was estimated at various time intervals by addition of 0.15

- 27 -

mm substrate S-2288 (Kabi) and assessing the rate of p-nitrophenylphosphate product release by absorbance change at 405 nm. Initial activity of the VIIQ11E33 preparation was less than 4% that of fully active VIIaQ11E33.

5 VIIQ11E33 was found to be a much better substrate for activation than wild-type factor VII. Figure 2 shows autoactivation of factor VIIQ11E33. The data were analyzed by the relationship in equation 5 (equation 7 of Fiore et al., 1994, *supra*).

10 $\ln[\text{VIIa}]_t = \ln[\text{VIIa}]_0 + \text{kcat} \cdot y \cdot t$ (eq. 5)

$\ln[\text{VIIa}]_t$ is the factor VIIa concentration at time t , kcat is the catalytic rate constant for factor VIIa acting on VII and y is the fractional saturation of VIIa sites. For wild-type factor VIIa, this relationship and 1 μM STF 15 gave a kcat of 0.0045/s and a kcat/Km ratio of $7 \times 10^3 \text{ M}^{-1}\text{s}^{-1}$. See, Fiore et al., 1994, *supra*. For the VIIQ11E33 enzyme, autoactivation was rapid (Figure 2) and it was only possible to estimate a lower limit for kcat . This was obtained from the VIIa doubling time of about 25 20 seconds ($\text{kcat} = (\ln 2)/t_{1/2}$). The resulting value ($\text{kcat}_{\min} = 0.03/\text{s}$), along with the substrate concentration of this reaction ($3.6 \times 10^{-8} \text{ M}$) and the assumption that $y=1.0$, gave a value for $\text{kcat}/[\text{S}] = 8 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$. This should be far below the true kcat/Km for VIIaQ11E33, but was 25 about 100-times greater than the value of kcat/Km for wild type factor VIIa/sTF estimated by Fiore et al., 1994, *supra*. Thus, the combination of VIIaQ11E33 enzyme and Factor VIIQ11E33 substrate was superior to wild type proteins in the activation step of coagulation. This 30 suggested that VIIQ11E33 was superior to wild type enzyme when coagulation conditions were minimal.

Enhanced activity of VIIaQ11E33: Once generated, factor VIIa activates either factor X or factor IX.

- 28 -

Activation of bovine factor X (0.1 μ M) by factor VIIa was carried out in 50 mM Tris-HCl buffer, pH 7.5 containing 100 mM NaCl, 5 mM calcium, various amounts of phospholipid (PS/PC, 25/75) and 1 mg/mL bovine serum albumin at 22.5°C. Factor VIIa (0.06 nM of VIIaQ11E33 or 0.6 nM wild type VIIa) was added at zero time and Xa activity at 1, 3 and 5 minute time points was determined. Aliquots of the reaction mixture (0.2 mL) were mixed with buffer (0.2 mL) containing 10 mM EDTA and 0.4 mM S-2222 (Kabi), a chromogenic substrate for factor Xa. Absorbance change at 405 nm was determined in a Beckman DU8 spectrophotometer. The amount of factor Xa generated was calculated from the extinction coefficient ($1 \times 10^4 M^{-1} cm^{-1}$) of the p-nitrophenylphosphate reaction product and a velocity of 33/sec for substrate hydrolysis by purified bovine Xa under the conditions of this assay.

Figure 3 compares the ability of wild type factor VIIa (open circles) and VIIaQ11E33 (closed circles) to activate factor X in a purified system. Again, VIIaQ11E33 was far superior to wild type factor VIIa in this reaction. The difference was greatest at low phospholipid concentrations and diminished to 2-fold at 200 μ g phospholipid per mL. This was expected from the fact that high membrane concentrations cause a greater portion of wild type VIIa to bind to the membrane. Once again, the increased function of VIIaQ11E33 was greatest under conditions of low phospholipid exposure.

Superior coagulation of VIIaQ11E33: Blood clotting assays were conducted at 37°C using the hand tilt method to detect clot formation. Human plasma (0.1 mL) was allowed to equilibrate at 37°C for 1 minute. Various reagents were added in a volume of 0.1 mL of standard buffer. Soluble tissue factor (50 nM) and phospholipid (PS/PC, 10/90, 75 μ g/mL) were added to the plasma, along with the factor VIIa concentration shown in

- 29 -

Figure 4 (0.1 - 32 nM). Finally, 0.1 mL of 25 mM CaCl₂ was added to start the reaction. Time to form a clot was measured. In most cases, the average and standard deviations of replicate samples was reported.

5 Figure 4 shows the coagulation times of wild type VIIa versus VIIaQ11E33 in normal human plasma. Coagulation was supported by sTF and added phospholipid vesicles. Endogenous wild type factor VII is approximately 10 nM in concentration, and had virtually
10 no impact on coagulation times. The background coagulation was 120 seconds, with or without sTF. Factor VIIaQ11E33 showed approximately 8-fold higher activity than the wild type VIIa under these assay conditions. Similar results were obtained with factor VIII-deficient
15 plasma, suggesting that the major pathway for blood clotting in this system involved direct activation of factor X by factor VIIa. Overall, factor VIIaQ11E33 was superior to wild type VIIa in procoagulant activity supported by membrane vesicles and soluble tissue factor.
20 Wild type zymogen had virtually no activity under these conditions, as indicated by similar background clotting times of 2 minutes, whether or not sTF was added.

Procoagulant activity with normal tissue factor:
Activity of VIIa and/or VIIQ11E33 with sTF was measured
25 in normal human plasma. Endogenous factor VII appeared to have no impact on coagulation time in this assay; the background clotting time was 2 minutes for plasma with or without soluble tissue factor. Soluble tissue factor (50 nM final concentration) and VIIa were added to the plasma
30 before the calcium solution. Coagulation time was assessed for samples containing various levels of VIIa or VIIaQ11E33. Two human plasma preparations were tested, normal and factor VIII-deficient.

Coagulation supported by normal tissue factor was
35 assayed with standard rabbit brain thromboplastin-HS

- 30 -

(HS=high sensitivity) containing calcium (Sigma Chemical Co.). This mixture contains both phospholipids and membrane-bound tissue factor. Rabbit brain thromboplastin-HS was diluted 1:100 in buffer and used in 5 the assay of VII (added in the form of normal human plasma, which contains 10 nM factor VII) and VIIQ11E33 (added as the pure protein). The thromboplastin (0.2 mL) was added to plasma (0.1 mL) to start the reaction and the time required to form a blood clot was measured.

10 Assays were also conducted with full strength thromboplastin, as described by the manufacturer.

At optimum levels of human thromboplastin, wild type VII showed a normal level of activity, about 1500 units per mg. This is approximately 25-fold less than 15 the activity of wild type factor VIIa (80,000 units per mg). The VIIQ11E33 gave approximately 1500-3000 units per mg under the standard assay conditions, only 2-fold greater than wild type VII.

The difference between wild type VII and VIIQ11E33 20 was much greater when the coagulation conditions were sub-optimal. Figure 5 shows the clotting times and zymogen concentrations in assays that contained 0.01-times the normal thromboplastin level. Under these conditions, VIIQ11E33 was approximately 20-fold more 25 active than wild type factor VII. Thus, greater efficacy of the VIIQ11E33 mutant was especially evident when coagulation conditions were limited, which is relevant to many situations *in vivo*.

Anticoagulant Activities of DEGR-VIIaQ11E33:

30 Standard coagulation assays were performed with normal human serum and human thromboplastin that was diluted 1:10 with buffer. The active site of factor VIIaQ11E33 was modified by DEGR as described by Sorenson, B.B. et al., 1997, *supra*. Figure 6 shows the clotting time of 35 DEGR-VIIaQ11E33 (0-4 nm) incubated with thromboplastin,

- 31 -

in calcium buffer, for 15 seconds before addition of the plasma. The time to form a clot was determined with the hand tilt method. Clotting time was approximately 45 seconds with about 1 nm of DEGR-VIIaQ11E33.

5 Example 2 - Circulatory Time of Factor VIIQ11E33 in the Rat: Two anesthetized (sodium nembutol) Sprague Dawley rats (325-350 g) were injected with 36 µg of factor VIIQ11E33 at time zero. Injection was through the juggler vein, into which a cannula had been placed. At 10 the times shown in Figure 7, blood was withdrawn from the carotid artery, into which a cannula had been inserted by surgery. The amount of factor VIIQ11E33 in the circulation was estimated from the clotting time of human factor VII-deficient plasma, to which 1 µL of a 1:10 dilution of the rat plasma was added. A 1:100 dilution 15 of rabbit brain thromboplastin-HS (Sigma Chemical Co.) was used. Coagulation was assessed by the manual tube tilt method as described in Example 1. The amount of factor VII activity in the plasma before injection of 20 VIIQ11E33 was determined and was subtracted as a blank. The concentration of factor VIIQ11E33 in the circulation is given as log nM. A sham experiment in which a third animal received the operation and cannulation but no factor VIIQ11E33 was conducted. The amount of factor VII 25 activity in that animal did not change over the time of the experiment (100 minutes). At the end of the experiment, the animals were euthanized by excess sodium nembutol.

The rats appeared normal throughout the experiment 30 with no evidence of coagulation. Therefore, the factor VIIQ11E33 did not cause indiscriminate coagulation, even in the post-operative rat. The circulation life-time of the VIIQ11E33 was normal (Figure 7), with approximately 40% of the protein being cleared in about 60 minutes and

- 32 -

an even slower disappearance of the remaining protein. This was similar to the rate of clearance of bovine prothrombin from the rat. Nelsestuen and Suttie, 1971, Biochem. Biophys. Res. Commun., 45:198-203. This is 5 superior to wild-type recombinant factor VIIa which gave a circulation half-time for functional assays of 20-45 minutes. Thomsen, M.K., et al., 1993, Thromb. Haemost., 70:458-464. This indicated that factor VIIQ11E33 was not recognized as an abnormal protein and that it was not 10 rapidly destroyed by coagulation activity. It appeared as a normal protein and should have a standard circulation lifetime in the animal.

Example 3 - Enhancement of the membrane site and activity of protein C: Bovine and human protein C show a high 15 degree of homology in the amino acids of their GLA domains (amino terminal 44 residues), despite about 10-fold higher membrane affinity of the human protein. Bovine protein C contains a proline at position 11 versus a histidine at position 11 of human protein C. The 20 impact of replacing proline-11 in bovine protein C with histidine, and the reverse change in human protein C, was examined. In both cases, the protein containing proline-11 showed lower membrane affinity, about 10-fold for bovine protein C and 5-fold for human protein C. 25 Activated human protein C (hAPC) containing proline at position 11 showed 2.4 to 3.5-fold lower activity than wild type hAPC, depending on the assay used. Bovine APC containing histidine-11 displayed up to 15-fold higher activity than wild type bAPC. This demonstrated the 30 ability to improve both membrane contact and activity by mutation.

Mutagenesis of Protein C: A full-length human protein C cDNA clone was provided by Dr. Johan Stenflo (Dept. of Clinical Chemistry, University Hospital, Malmö,

- 33 -

Sweden). The bovine protein C cDNA clone was provided by Dr. Donald Foster (ZymoGenetics, Inc., USA). The GenBank accession number for the nucleotide sequence of bovine protein C is K02435, NID g163486 and is K02059, NID 5 g190322 for the nucleotide sequence of human protein C.

Site-directed mutagenesis was performed by a PCR method. For human protein C mutagenesis of histidine-11 to proline, the following oligonucleotides were synthesized: A, 5'-AAA TTA ATA CGA CTC ACT ATA GGG AGA 10 CCC AAG CTT-3' (SEQ ID NO:7) (corresponding to nucleotides 860-895 in the vector pRc/CMV) to create a *Hind III* site between pRc/CMV and protein C. B, 5'-GCA CTC CCG CTC CAG GCT GCT GGG ACG GAG CTC CTC CAG GAA-3' (SEQ ID NO:8) (corresponding to the amino acid residues 15 4-17 in human protein C, the 8th residue in this sequence was mutated from that for human protein C to that of bovine protein C, as indicated by the underline).

For bovine protein C mutagenesis of proline-11 to histidine, the following oligonucleotides were 20 synthesized: A, (as described above); C, 5'-ACG CTC CAC GTT GCC GTG CCG CAG CTC CTC TAG GAA-3' (SEQ ID NO:9) (corresponding to amino acid residues 4-15 in bovine protein C, the 6th amino acid was mutated from that for bovine protein C to that of human protein C as marked 25 with underline); D, 5'-TTC CTA GAG GAG CTG CGG CAC GGC AAC GTG GAG CGT-3' (SEQ ID NO:10) (corresponding to amino acid residues 4-15 in bovine protein C, the 7th amino acid was mutated from that for bovine protein C to that of human protein C; mutated nucleotides are underlined); 30 E, 5'-GCA TTT AGG TGA CAC TAT AGA ATA GGG CCC TCT AGA-3' (SEQ ID NO:11) (corresponding to nucleotides 984-1019 in the vector pRc/CMV), creating a *Xba I* site between pRc/CMV and protein C).

Both human and bovine protein C cDNAs were cloned 35 into the *Hind III* and *Xba I* sites of the expression

- 34 -

vector pRc/CMV. Human protein C cDNA containing the 5' terminus to amino acid-17 was PCR amplified with intact human protein C cDNA and primers A and B. The volume for the PCR reaction was 100 μ l and contained 0.25 μ g of 5 template DNA, 200 μ M each of the four deoxyribonucleoside triphosphates, 0.5 mM of each primer and 2.5 U of Pwo-DNA polymerase (Boehringer Mannheim) in Tris-HCl buffer (10 mM Tris, 25 mM KCl, 5 mM $(\text{NH}_4)_2\text{SO}_4$, and 2 mM MgSO₄, pH 8.85). Samples were subjected to 30 cycles of PCR 10 consisting of a 2 minute, 94°C denaturation period, a 2 minute, 55°C annealing period, and a 2 minute, 72°C elongation period. After amplification, the DNA was electrophoresed through an 0.8% agarose gel in 40 mM Tris-acetate buffer containing 1 mM EDTA. PCR products 15 were purified with JET Plasmid Miniprep-Kit (Saveen Biotech AB, Sweden). Human protein C cDNA containing respective mutations was cleaved by *Hind III* and *Bsr BI*, and then cloned into pRc/CMV vector that was cleaved by *Hind III/Xba I* and that contained human protein C 20 fragment from *Bsr BI* to the 3' terminus to produce a human protein C full length cDNA with the mutation.

Bovine protein C cDNA, containing the 5' terminus through amino acid-11, was PCR amplified with intact human protein C cDNA and primers A and C. Bovine protein 25 C cDNA from amino acid 11 to the 3' terminus was amplified with intact human protein C cDNA and primers D and E. These two cDNA fragments were used as templates to amplify full length bovine protein C cDNA containing mutated amino acids with primers A and E. PCR reaction 30 conditions were identical to those used for hAPC. The bovine protein C cDNA containing the respective mutations was cleaved by *Hind III* and *Bsu 36I*, and the *Hind III/Bsu36I* fragment was cloned into pRc/CMV vector containing intact bovine protein C fragments from the *Bsu 35 36I* to the 3' terminus to produce full-length bovine

- 35 -

protein C cDNA containing the mutation. All mutations were confirmed by DNA sequencing prior to transfection.

Cell Culture and Expression: The adenovirus-transfected human kidney cell line 293 was grown in DMEM medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml of penicillin, 100 U/ml streptomycin and 10 µg/ml vitamin K₁. Transfection was performed using the lipofectin method. Felgner, P.L. et al., 1987, Proc. Natl. Acad. Sci. USA, 84:7413-7417. Two µg of DNA was diluted to 0.1 mL with DMEM containing 2 mM of L-glutamine medium. Ten µL of Lipofectin (1 mg/ml) was added to 100 µL of DMEM containing 2 mM L-glutamine medium. DNA and lipofectin were mixed and left at room temperature for 10-15 min. Cell monolayers (25-50% confluence in 5-cm petri-dishes) were washed twice in DMEM with 2 mM L-glutamine medium. The DNA/lipid mixture was diluted to 1.8 mL in DMEM containing 2 mM L-glutamine medium, added to the cells and incubated for 16 hours. The cells were fed with 2 mL of complete medium containing 10% calf serum, left to recover for another 48-72 hours and then trypsinized and seeded into 10-cm dishes with selection medium (DMEM containing 10% serum and 400 µg/mL of Geneticin) at 1:5. Yan, S.C.B. et al., 1990, Bio/Technology 655-661. Geneticin-resistant colonies were obtained after 3-5 weeks of selection. Twenty four colonies from each DNA transfection were picked, grown to confluence and the media screened for protein C expression with a dot-blot assay using monoclonal antibody HPC4 (for human protein C) and monoclonal antibody BPC5 (for bovine protein C). Clones producing high amounts of protein were isolated and grown until confluence in the presence of 10 µg/mL of vitamin K₁.

The purification of bovine recombinant protein C and its mutant were based on the method described

- 36 -

previously with some modifications. Rezair, A.R., and Esmon, C.T., 1992, J. Biol. Chem., 267:26104-26109. Conditioned serum-free medium from stably transfected cells was centrifuged at 5000 rpm at 4°C for 10 minutes.

5 The supernatant was filtered through 0.45 µm of cellulose nitrate membranes (Micro Filtration Systems, Japan). EDTA (5 mM, final concentration) and PPACK (0.2 µM, final concentration) were added to the conditioned medium from 293 cells, then passed through a Pharmacia FFQ anion-

10 exchange column at room temperature using Millipore Con Sep LC100 (Millipore, USA). The protein was eluted with a CaCl₂ gradient (starting solution, 20 mM Tris-HCl/150 mM NaCl, pH 7.4; limiting solution, 20 mM Tris-HCl/150 mM NaCl/30 mM CaCl₂, pH 7.4). After removal of the CaCl₂ by

15 dialysis and Chelex 100 treatment, the protein was reabsorbed to a second FFQ column, then eluted with an NaCl gradient (starting solution 20 mM Tris-HCl/150 mM NaCl, pH 7.4; limiting solution, 20 mM Tris-HCl/500 mM NaCl, pH 7.4). At this point in the purification, wild-

20 type and the mutant recombinant bovine protein C were homogeneous as determined by SDS-PAGE.

The first column used for purification of wild-type and mutant recombinant human protein C was the same as that described for bovine protein C. The

25 chromatographic method described by Rezair and Esmon was employed with some modifications described for the method of protein S purification. Rezair, A.R., and Esmon, C.T., 1992, *supra*; He, Z. et al., 1995, Eur. J. Biochem., 227:433-440. Fractions containing protein C from anion-

30 exchange chromatography were identified by dot-blot. Positive fractions were pooled and applied to an affinity column containing the Ca²⁺-dependent antibody HPC-4. The column was equilibrated with 20 mM Tris-HCl, 150 mM NaCl, pH 7.4, containing 5 mM Benzamidine-HCl and 2 mM CaCl₂.

35 After application, the column was washed with the same

- 37 -

buffer containing 1 M NaCl. Protein C was then eluted with 20 mM Tris-HCl, 150 mM NaCl and 5 mM EDTA, pH 7.4, containing 5 mM Benzamidine-HCl. After purification, the purity of all human and bovine recombinant protein C 5 preparations was estimated by SDS-PAGE followed by silver staining. Proteins were concentrated using YM 10 filters (Amicon), then dialyzed against buffer (50 mM Tris-HCl and 150 mM NaCl, pH 7.4) for 12 hours and stored at -70°C. The concentrations of proteins were measured by 10 absorbance at 280 nm.

Association of normal and mutant protein C

molecules with membranes: LUVs and SUVs were prepared by methods described in Example 1. Light scattering at 90° to the incident light was used to quantitate protein-15 membrane binding as described above for Factor VII (25 µg/mL of PS/PC, (25/75) at 5 mM calcium (0.05 M Tris buffer-0.1 M NaCl, pH 7.5).

Bovine protein C containing histidine at position 11 interacted with membranes with about 10-fold higher 20 affinity than wild type protein. When fit to equation 2, the data gave K_D values of 930±80 nM for protein C-H11 and 9200±950 nM for wild type protein C (Figure 8A). The difference in affinity corresponded to about 1.4 kcal/mol at 25°C. In fact, membrane affinity of bovine protein C-25 H11 was almost identical to that of native human protein C (660 nM, Figure 8B). This suggested that proline 11 formed a major basis for differences between the membrane binding site of human and bovine proteins.

The reverse substitution, replacement of His-11 of 30 human protein C by proline, decreased membrane affinity (Figure 8B). When fit to equation 2, these data gave K_D values of 660±90 nM for wild type human protein C and 3350 ±110 nM for human protein C-P11. The impact of proline introduction was only slightly less than that of 35 proline in the bovine proteins.

- 38 -

Impact of proline-11 on activity of activated protein C: Activated protein C was generated by thrombin cleavage, using identical conditions for both the wild type and mutant proteins. Approximately 150 µg of the 5 various protein C preparations (1 mg/mL) were mixed with bovine thrombin (3 µg) and incubated at 37°C for 5 hours. The reaction product was diluted to 0.025 M Tris buffer-0.05 M NaCl and applied to a one mL column of SP-Sephadex C-50. The column was washed with one mL of the same 10 buffer and the flow-through was pooled as activated protein C. Approximately 65-80% of the protein applied to the column was recovered. APC activity was determined by proteolysis of S2366 (0.1 mM) at 25°C. The preparations were compared to standard preparations 15 obtained on larger scale. Standard human APC was provided by Dr. Walter Kisiel. For bovine proteins, the standard was a large-scale preparation of thrombin-activated APC. The activity of bovine APC was consistent for all preparations of normal and mutant proteins ($\pm 5\%$). 20 Two preparations of bovine APC were used for comparisons. Human APC generated from thrombin was 55 to 60% as active as the standard. The concentrations reported in this study were based on activity toward S2366, relative to that of the standard.

25 Standard APTT test used bovine or human plasma and standard APTT reagent (Sigma Chemical Co.) according to manufacturers instructions. Alternatively, phospholipid was provided in the form of vesicles formed from highly purified phospholipids. In this assay, bovine plasma 30 (0.1 mL) was incubated with either kaolin (0.1 mL of 5 mg/mL in 0.05 M Tris buffer, 0.1 M NaCl, pH 7.5) or ellagic acid (0.1 mM in buffer) for 5 minutes at 35°C. Coagulation was started by adding 0.1 mL of buffer containing phospholipid and the amounts of APC shown, 35 followed by 0.1 mL of 25 mM calcium chloride. All

- 39 -

reagents were in standard buffer containing 0.05 M Tris buffer, 0.1 M NaCl, pH 7.5. An average of a 14-fold higher concentration of wild type bAPC was needed to duplicate the impact of the H11 mutant. Coagulation time 5 at 10 nM bAPC-H11 was greater than 120 minutes. Standard APTT reagent (Sigma Chemical Co.) gave a clotting time of about 61 seconds at 35°C with this plasma. Time required to form a clot was recorded by manual technique. The amount of phospholipid was designed to be the limiting 10 component in the assay and to give the clotting times shown. The phospholipids used were SUVs (45 µg/0.4 mL in the final assay, PS/PC, 10/90) or LUVs (120 µg/0.4 mL in the final assay, PS/PC, 25/75).

The anticoagulant activity of activated protein C 15 was tested in several assays. Figure 9 shows the impact on the APTT assay, conducted with limiting phospholipid. Under the conditions of this assay, coagulation times decreased in a nearly linear, inverse relationship with phospholipid concentration. Approximately 14-times as 20 much wild type bovine APC was needed to equal the effect of bovine APC-H11.

Parts of the study in Figure 9 were repeated for membranes of PS/PC (25/75, LUV). Again, activity was limited by phospholipid, and its concentration was 25 adjusted to give a control clotting time of 360 seconds (120 µg of 25% PS in the 0.4 mL assay). Approximately 15-fold more wild type enzyme was needed to equal the impact of the H11 mutant. Finally, standard APTT reagent (Sigma Chemical Co., standard clotting time 50±2 seconds) 30 was used. Approximately 10.0±0.7 nM of wild type enzyme was needed to double the coagulation time to 102±5 seconds. The same impact was produced by 2.2±0.1 nM bovine APC-H11. Phospholipid was not rate limiting in the standard assay so a smaller impact on membrane 35 affinity may be expected.

- 40 -

Results for human proteins are shown in Figure 8B. About 2.5 times as much human APC containing proline-11 was required to prolong coagulation to the extent of wild type APC. A lower impact of proline-11 introduction may 5 reflect the smaller differences in membrane affinity of the human proteins (Figure 9B).

Inactivation of factor Va: Factor Va inactivation was assayed by the method of Nicolaes et al., 1996, Thrombosis and Haemostasis, 76:404-410. Briefly, for 10 bovine proteins, bovine plasma was diluted 1000-fold by 0.05 M Tris, 0.1 M NaCl, 1 mg/mL bovine serum albumin and 5 mM calcium at pH 7.5. Phospholipid vesicles (5 µg/0.24 mL assay) and 5 µL of 190 nM thrombin were added to activate factor V. After a 10-minute incubation at 37°C, 15 APC was added and the incubation was continued for 6 minutes. Bovine prothrombin (to 10 µM final concentration) and factor Xa (0.3 nM final concentration) were added and the reaction was incubated for one minute at 37°C. A 20 µL sample of this activation reaction was 20 added to 0.38 mL of buffer (0.05 M Tris, 0.1 M NaCl, 5 mM EDTA, pH 7.5) containing S2288 substrate (60µM). The amount of thrombin was determined by the change in absorbance at 405 nM ($\epsilon=1.0*10^4 \text{ M}^{-1}\text{s}^{-1}$, k_{cat} for thrombin=100/s). For human proteins, human protein S-deficient plasma (Biopool Canada, Inc.) was diluted 100-fold, factor Va was activated by human thrombin and the 25 factor Va produced was assayed with the reagents used for the bovine proteins.

Bovine APC-H11 was 9.2-fold more active than wild 30 type (Figure 10A) in inactivating factor Va. As for membrane binding (above), the impact of proline-11 was less with the human proteins, with an average of 2.4-fold difference between the curves drawn for wild type and P-11 mutant (Figure 10B). Similar results were obtained 35 with normal human plasma.

- 41 -

Example 4 - Identification of an archetype membrane affinity for the membrane contact site of Vitamin K-dependent proteins: Comparison of various human and bovine protein C mutants and other vitamin K-dependent polypeptides led to a proposed membrane contact site archetype. The electrostatic archetype consists of an electropositive core on one surface of the protein, created by bound calcium ions, surrounded by a halo of electronegative charge from amino acids of the protein.

The closer a member of this protein family approaches this electrostatic pattern, the higher its affinity for membranes.

Phospholipid vesicles, wild type bovine protein C, protein-membrane interaction studies, activation and quantitation of protein C, and activity analysis were as described in Example 3.

Recombinant, mutant protein C was generated by the following procedures. Site-directed mutagenesis was performed by a PCR method. The following oligonucleotides were synthesized: **A**, as described in Example 3; **F**, 5'-GCA TTT AGG TGA CAC TAT AGA ATA GGG CCC TCT AGA -3' (SEQ ID NO:11) (corresponding to nucleotides 984-1019 in the vector pRc/CMV), creating a Xba I site between pRc/CMV and protein C; **G**, 5'-GAA GGC CAT TGT GTC TTC CGT GTC TTC GAA AAT CTC CCG AGC-3' (SEQ ID NO:12) (corresponding to amino acid residues 40-27 in bovine protein C, the 8th and 9th amino acids were mutated from QN to ED as marked with underline); **H**, 5'-CAG TGT GTC ATC CAC ATC TTC GAA AAT TTC CTT GGC-3' (SEQ ID NO:13) (corresponding to amino acid residues 38-27 in human protein C, the 6th and 7th amino acids in this sequence were mutated from QN to ED as indicated with the underline); **I**, 5'-GCC AAG GAA ATT TTC GAA GAT GTG GAT GAC ACA CTG-3' (SEQ ID NO:14) (corresponding to amino acid residues 27-38 in human protein C, the 6th and 7th amino

- 42 -

acids in this sequence were mutated from QN to ED as indicated with underline); J, 5'-CAG TGT GTC ATC CAC ATT TTC GAA AAT TTC CTT GGC-3' (SEQ ID NO:15) (corresponding to amino acid residues 38-27 in human protein C, the 7th 5 amino acids in this sequence were mutated from Q to E as indicated with underline); K, 5'-GCC AAG GAA ATT TTC GAA AAT GTG GAT GAC ACA CTG-3' (SEQ ID NO:16) (corresponding to amino acid residues 27-38 in human protein C, the 6th amino acid in this sequence was mutated from Q to E as 10 indicated with underline);

Both bovine and human protein C full length cDNAs were cloned into the Hind III and Xba I site of the vector pRc/CMV. To obtain bovine protein C mutant E33D34, PCR amplification of the target DNA was performed 15 as follows. Bovine protein C cDNA containing the 5' terminus to the amino acid at position 40, was amplified with intact bovine protein C cDNA and primers A and C. The PCR reaction conditions were as described in Example 3. The sample was subjected to 30 cycles of PCR 20 consisting of a 2 min denaturation period at 94°C, a 2 min annealing period at 55°C and a 2 min elongation period at 72°C. After amplification, the DNA was electrophoresed through an 0.8% agarose gel in 40 mM Tris-acetate buffer containing 1 mM EDTA. The PCR 25 products were purified with The Geneclean III kit (BIO 101, Inc. USA), and the PCR fragment of bovine protein C cDNA containing the respective mutations was cleaved by Hind III and Bbs I. The Hind III/Bbs I fragment and the human protein C fragment (Bbs I - 3' terminus) were 30 cloned into the Hind II and Xba I sites of pRc/CMV vector to produce a full-length bovine protein C cDNA with the mutations. Bovine protein C mutant H11 E33 D34 was created in the same way, but used bovine protein C mutant H11 as a template in the PCR reaction.

- 43 -

Human protein C cDNA containing the 5' terminus to amino acid-38 was PCR amplified with intact human protein C cDNA and primers A and D. Human protein C cDNA from amino acid 27 to the 3' terminus was amplified with 5 intact human protein C cDNA and primers B and E. These two cDNA fragments were used as templates to amplify full length bovine protein C cDNA containing mutated amino acids (E33 D34) with primers A and B. Human protein C mutant E33 was obtained by the following steps: human 10 protein C cDNA containing the 5' terminus to amino acid 38 was amplified with intact human protein C cDNA and primers A and F. Human protein C cDNA from amino acid 27 to the 3' terminus was amplified with intact human protein C cDNA and primers B and G. These two cDNA 15 fragments were used as templates to amplify full length bovine protein C cDNA containing mutated amino acids (E33) with primers A and B. The PCR mixture and program were described above. The human protein C PCR products containing respective mutations were cleaved by Hind III 20 and Sal I, and then the fragment (Hind III - Sal I) together with intact human protein C fragment (Sal I - 3' terminus) were cloned into the Hind III and Xba I sites of pRc/CMV vector to produce the full length human protein C cDNA with the respective mutations. All 25 mutations were confirmed by DNA sequencing prior to transfection.

The adenovirus-transfected human kidney cell line 293 was cultured and transfected as described in Example 3. Bovine and human recombinant protein C and mutants 30 were purified as described in Example 3.

The vitamin K-dependent proteins were classified into four groups on the basis of their affinities for a standard membrane (Table 4). Sequences of the amino terminal residues of some relevant proteins including 35 human protein C (hC), bovine protein C (bC), bovine

- 44 -

prothrombin (bPT), bovine factor X (bX), and human factor VII (hVII) are given for reference, where X is Gla (γ -carboxyglutamic acid) or Glu.

bPT: ANKGFLXXVRK₁,GNLXRXC_LXX₂,PCSRXXAFXA₃,LXSLSATDAF₄,WAKY (SEQ ID NO:17)
5 bx: ANS-FLXXVKQ₁,GNLXRXC_LXX₂,ACSLXXARXV₃, FXDAXQTDXF₄,WSKY (SEQ ID NO:18)
hC: ANS-FLXXLRH₁,SSLXRXCIXX₂,ICDFXXAKXI₃,FQNVDDTLAF₄,WSKH (SEQ ID NO:1)
bC: ANS-FLXXLRP₁,GNVXRXC_SXX₂,VCXFXXARXI₃,FQNTXDTMAF₄,WSFY (SEQ ID NO:2)
hVII: ANA-FLXXLRP₁,GSLXRCKXX₂,QCSFXXARXI₃,FKDAXRTKLF₄,WISY (SEQ ID NO:3)

- 45 -

TABLE 4
Charges and Affinity

	Residue						
	11 + 29 + 33 + 34 = Sum					Total	K _D (nM)
Class I							
bZ	-2	+	-2	-1	-4	-6	0.2 ^a -32
hZ	-2	+	-2		-3	-5	2.0 ^a -170
Class II							
bPT-TNBS			-2		-2	-1	<10
hVII-Q11E33		+	-2	-1	-2	-2	10
hS		+	-2	-1	-2	-2	40
bX		+	-2	-1	-2	-3	40
bC-E33D34	P	+	-2	-1	-2	-4	125
hX	+	+	-2	-1	-1	-2	160
bPT	+		-2		-1	0	100
hPT	+		-2		-1	-1	-
bS	+	+	-2		0	0	120
Class III							
bIX		+	-2		-1	-1	1000
hIX		+	-2		-1	-1	1000
hC		+			+1	-2	660
bC-H11		+			+1	-1	930

- 46 -

Class IV							
5	hC	P	+		+1	-2	3300
	hVII	P	+	+	-1	+1	4000
	bC	P	+		+1	-1	9200
	bVII	P	+	+	+1	0	15000

^a Higher affinity value equals $k_{dissociation}/1 \times 10^7 M^{-1} s^{-1}$; the denominator is a typical $k_{association}$ for other proteins.

In Table 4, vitamin K-dependent polypeptide mutants are in bold. The total charge (residues 1-34) includes 7 calcium ions (+14) and the amino terminus (+1).

Protein Z was assigned to class I on the basis of its dissociation rate constant, which was 100 to 1000 times slower than that of other proteins. If protein Z displayed a normal association rate constant (about $10^7 M^{-1}s^{-1}$) the K_d would be about $10^{-10} M$. Wei, G.J. et al., 1982, Biochemistry, 21:1949-1959. The latter affinity may be the maximum possible for the vitamin K proteins. Class IV proteins differed from class III in the presence of proline-11, which may alter affinity by non-electrostatic means.

While a relatively weak correlation existed between membrane affinity and net negative charge on residues 1-34, an excellent correlation was found when only residues 5, 11, 29, 33 and 34 were considered (Table 4). The latter amino acids are located on the surface of the protein. A number of proteins were modeled by amino acid substitution into the prothrombin structure and their electrostatic potentials were estimated by the program DelPhi. A sketch patterned after the electrostatic potential of bovine protein Z is shown in Figure 11. Electronegative sites at 7, 8, 26, 30, 33, 34 and 11 produce a halo of electronegative charge surrounding a cationic core produced by the calcium-lined

- 47 -

pore (Figure 11). The closer a protein structure approaches this structure, the higher its affinity for the membrane. This correlation is apparent from the wild-type proteins, the mutants and chemically modified 5 proteins.

The pattern for other structures can be extrapolated from examination of the charge groups that are absent in other proteins. For example, Lys-11 and Arg-10 of bovine prothrombin generate high 10 electropositive regions in their vicinity; the lack of Gla-33 in protein C and Factor VII create less electronegativity in those protein regions. In all cases, highest affinity corresponded to a structure with an electropositive core that was completely surrounded by 15 electronegative protein surface, as shown for protein Z. The exceptions to this pattern are the proteins with Pro-11, which may lower affinity by a structural impact and ser-12 (human protein C), which is a unique uncharged residue.

20 To further test the hypothesis of an archetype for electrostatic distribution, site-directed mutagenesis was used to replace Gln33Asn34 of bovine and human protein C with Glu33Asp34 (SEQ ID NO:19). Glu33 should be further modified to Gla during protein processing. These changes 25 altered the electrostatic potential of bovine protein C to that of bovine factor X. The membrane affinity of the mutant protein was expected to be lower than that of factor X due to the presence of proline-11. Indeed, the bovine protein C mutant gave a membrane affinity similar 30 to that of bovine prothrombin (Figure 12A), and slightly less than that of bovine factor X (Table 4).

More interesting was that clot inhibition by APC was greater for the mutant than for the wild type enzyme (Figure 12B, C). Inclusion of results for the P11H 35 mutant of bovine protein C from Example 3 showed that a

- 48 -

family of proteins could be produced, each with different membrane affinity and activity, by varying the amino acid substitutions at positions 11, 33 and 34.

Human protein C mutants containing E33 and E33D34 5 resulted in a small increase in membrane binding affinity (Figure 13a). Activity of these mutants was slightly less than the wild-type enzyme (Figure 13b). Results with mutants of bovine protein C suggest that failure of the E33D34 mutation in the human protein may arise from 10 H11 and/or other unique amino acids in the protein.

Figure 14A shows that the H11 mutant of bovine protein C bound to the membrane with about 10-fold higher affinity than wild type protein, the E33D34 mutant bound with about 70-times the affinity, but that the triple mutant, 15 H11E33D34, was only slightly better than the H11 mutant. This relationship was mirrored in the activity of APC formed from these mutants (Figure 14B). This result suggested that the presence of H11 reduced the impact of E33D34 on membrane binding affinity.

20 These results indicated that introduction of E33D34 may not be optimal for all proteins. Consequently, other mutations may be desirable to create human protein C that will use E33D34 and have maximum increased membrane affinity. The result with the bovine 25 protein suggested that histidine 11 may be the primary cause of this phenomenon. Consequently, H11 may be altered to glutamine or to another amino acid in human protein C, along with the E33D34 mutation. Another amino acid that may impact the affinity is the serine at 30 position 12, an amino acid that is entirely unique to human protein C. These additional changes should produce proteins with enhanced membrane affinity.

The electrostatic archetype was also tested by comparison of human and bovine factor X. The presence of 35 lysine-11 in human factor X suggests that it should have

- 49 -

lower affinity than bovine factor X. This prediction was borne out, by the result shown in Figure 15.

Earlier studies had shown that trinitrobenzenesulfonic acid (TNBS) modification of 5 bovine and human prothrombin fragment 1 had relatively little impact (0 to 5-fold) on membrane affinity. Weber, D.J. et al., 1992, J. Biol. Chem., 267:4564-4569; Welsch, D.J. et al., 1988, Biochemistry, 27:4933-4938. Conditions used for the reaction resulted in 10 derivatization of the amino terminus, a change that is linked to lowered membrane affinity. Welsch, D.J. and Nelsestuen, G.L., 1988, Biochemistry, 27:4939-4945. Protein modification in the presence of calcium, which protects the amino terminus, resulted in TNBS-modified 15 protein with much higher affinity for the membrane than native fragment 1.

The suggestion that protein Z constitutes the archetype was based on its dissociation rate constant and that a normal association rate would generate a $K_D=10^{-10}$ M. 20 Whether this value can be reached is uncertain. It is possible that the slow association rate of protein Z is caused by improper protein folding, resulting in a low concentration of the membrane-binding conformation. If conditions can be altered to improve protein folding, 25 association rates of protein Z should improve. Indeed, the association rate constant for protein Z was improved by alteration of pH. The basis for this observation may be related to an unusual feature of the prothrombin structure which is the close placement of the amino 30 terminus (+1 at pH 7.5) to calcium ions 2 and 3. The +1 charge on the amino terminus is responsible for the slight electropositive region just above Ca-1 in Figure 11. Charge repulsion between Ca and the amino terminal may destabilize protein folding and could be a serious 35 problem for a protein that had low folding stability.

- 50 -

Table 5 provides additional support for the archetype model. It shows the relationship between distance of ionic groups from strontium ions 1 and 8 (corresponding to calcium 1 and an extra divalent metal 5 ion found in the Sr x-ray crystal structure of prothrombin). The pattern suggests that the closer an ionic group is to these metal ions, the higher its impact 10 on membrane affinity. The exception is Arg-16, which contributes to the charge of the electropositive core.

Higher affinity is correlated with electronegative charge 15 at all other sites. This correlation also applies to the GLA residues.

TABLE 5
Distance to Sr-1, 8 and Ion Importance.

		Distance (\AA) to: Impact/ion			
	Position	Atom ^a	Sr-1	Sr-8	
15	(A.A-Protein)				
	3 (K-PT)	ε -N	22.1	21.7	Low or Unknown
20	5 (K-IX)	para-C(F)	20.1	20.8	"
	19 (K/R-VII)	C5(L)	20.2	17.8	"
	22 (K-IX)	C4(P)	17.0	18.5	"
	10 (R)	C6(R)	16.8	12.9	"
	25 (R-PT)	C6(R)	11.2	13.8	"
	24 (X/D-PC)	O(S)	8.1	12.0	"
25	11 (K-PT, hX, bS; Gla-PZ)				
		ε -C(K)	14.7	7.4	3-10-fold ^b
	33 (Gla)	γ -C(E)	11.6	7.5	"
	34 (D)	O(S)	15.3	12.1	"
30	29 (R)	para-C(F)	7.5	8.4	"
	16 (R)	C6(R)	14.2	10.6	" ^c

- 51 -

Gla residue ^d					
Low importance:					
5	7		12.8	13.3	+2 (<2)
	15		20	16	<2 (<2)
	20		19.4	17.8	<2 (<2)
	21		17.2	15	4 (3)
	33		11.6	7.5	? ^e (<2)
High importance:					
10	8		8.7	10.9	? ^e (20)
	26		3.6	9.5	? ^e (50)
	17		11.1	9.1	>200(100)
	27		8.4	10.6	>200(85)
	30		3.4	4.2	>200(25)

^a Distances are from this atom of bovine prothrombin (residue of prothrombin used in measurement is given in parentheses) to strontium 1 and 8 of the Sr-Prothrombin fragment 1 structure. Seshadri et al. 1994, Biochemistry 33:1087-1092. ^b For all but 16-R, cations lower affinity and anions increase affinity.

^c Thariath et al. 1997 Biochem. J. 322:309-315. ^d Impact of Glu to Asp mutations, distances are averages for the gamma-carboxyl-carbons.

$K_D(K_m)$ data are from Ratcliffe et al. 1993 J. Biol. Chem. 268:24339-45.

^e Binding was of lower capacity or caused aggregation, making comparisons less certain.

The results in Figure 15C show that the association rate for protein Z was substantially improved at pH 9, where an amino terminal should be uncharged. The rate constant obtained from these data was about 12-fold higher at pH 9 than at pH 7.5 (Figure 15C).

- 52 -

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

- 53 -

Claims

What is claimed is:

1. A vitamin K-dependent polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.
2. The polypeptide of claim 1 wherein said GLA domain is from amino acid 1 to about amino acid 45.
- 10 3. The polypeptide of claim 1, wherein said amino acid substitution is at amino acid 11, 12, 29, 33 or 34.
4. The polypeptide of claim 3, wherein said amino acid substitution is at amino acid 11, 33 or 34.
- 15 5. The polypeptide of claim 1, wherein said polypeptide comprises Protein C or Activated Protein C.
6. The polypeptide of claim 5, wherein said amino acid substitution comprises a glutamic acid residue at amino acid 33 and an aspartic acid residue at amino acid 34 (SEQ ID NO:19).
- 20 7. The polypeptide of claim 6, wherein said amino acid substitution further comprises a glutamine at amino acid 11 (SEQ ID NO:20).
8. The polypeptide of claim 6, wherein said amino acid substitution further comprises a glutamic acid at 25 amino acid 11 (SEQ ID NO:21).

- 54 -

9. The polypeptide of claim 7 or claim 8, wherein said amino acid substitution further comprises a glycine at amino acid 12 (SEQ ID NO:24 or SEQ ID NO:35).

10. The polypeptide of claim 1, wherein said
5 polypeptide comprises Factor VII or Factor VIIa.

11. The polypeptide of claim 10, wherein said amino acid substitution comprises a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

10 12. The polypeptide of claim 1, wherein said polypeptide comprises Factor IX or Factor IXa.

13. The polypeptide of claim 1, wherein said polypeptide comprises active-site modified Factor VIIa.

14. The polypeptide of claim 13, wherein said
15 amino acid substitution comprises a glutamine residue at amino acid 11 and a glutamic acid residue at amino acid 33 (SEQ ID NO:30).

15. The vitamin K-dependent polypeptide of claim 1, wherein said modified GLA domain comprises an amino
20 acid sequence which, in the calcium saturated state, forms a tertiary structure having a cationic core with a halo of electronegative charge.

16. An isolated nucleic acid encoding a vitamin K-dependent polypeptide, wherein said vitamin K-dependent
25 polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide,

- 55 -

said modified GLA domain comprising at least one amino acid substitution.

17. A mammalian host cell comprising a nucleic acid vector, said vector encoding a vitamin k-dependent polypeptide, said vitamin k-dependent polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin k-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a vitamin K-dependent polypeptide effective to inhibit clot formation in a mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

20 19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a vitamin K-dependent polypeptide effective to increase clot formation in a mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

20. A vitamin K-dependent polypeptide for use in treating a clotting disorder, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain

- 56 -

that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

5 21. Use of a vitamin K-dependent polypeptide in the manufacture of a medicament for the treatment of a clotting disorder, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to
10 a corresponding native vitamin K-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

15 22. A method of decreasing clot formation in a mammal comprising administering an amount of a vitamin K-dependent polypeptide effective to decrease clot formation in said mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin k-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

25 23. A method of increasing clot formation in a mammal comprising administering an amount of a vitamin K-dependent polypeptide effective to increase clot formation in said mammal, wherein said vitamin K-dependent polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin k-dependent polypeptide, said modified GLA domain comprising at least one amino acid substitution.

Fig. 1A





Fig. 1B

SUBSTITUTE SHEET (RULE 26)



Fig. 2**SUBSTITUTE SHEET (RULE 26)**

Fig. 3

SUBSTITUTE SHEET (RULE 26)



Fig. 4**SUBSTITUTE SHEET (RULE 26)**

Fig. 5



SUBSTITUTE SHEET (RULE 26)







Fig. 6**SUBSTITUTE SHEET (RULE 26)**

Fig. 7

SUBSTITUTE SHEET (RULE 26)

Fig. 8A*Fig. 8B*

SUBSTITUTE SHEET (RULE 26)

Fig. 9A*Fig. 9B*

SUBSTITUTE SHEET (RULE 26)




Fig. 10 A*Fig. 10 B*

Fig. 11



SUBSTITUTE SHEET (RULE 26)

Fig.12A




Fig.12B





Fig.12C



SUBSTITUTE SHEET (RULE 26)

Fig. 13A

FIGURE 1-COMPARISON OF HUMAN PROTEIN C MUTANTS
MEMBRANE BINDING-HUMAN PROTEIN C






Fig. 13B

SUBSTITUTE SHEET (RULE 26)

Fig. 14 A*Fig. 14 B*




Fig. 15

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> Regents of the University of Minnesota

<120> MODIFIED VITAMIN K-DEPENDENT
POLYPEPTIDES

<130> 09531/002W01

<150> 08/955,636
<151> 1997-10-23

<160> 35

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 1

Ala Asn Ser Phe Leu Xaa Xaa Leu Arg His Ser Ser Leu Xaa Arg Xaa
1 5 10 15
Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Gln
20 25 30
Asn Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
35 40

<210> 2

<211> 44

<212> PRT

<213> Bos taurus

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 2

Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Pro Gly Asn Val Xaa Arg Xaa
1 5 10 15
Cys Ser Xaa Xaa Val Cys Xaa Phe Xaa Xaa Ala Arg Xaa Ile Phe Gln
20 25 30
Asn Thr Xaa Asp Thr Met Ala Phe Trp Ser Phe Tyr
35 40

<210> 3

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 3

Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Pro Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Arg Xaa Ile Phe Lys
 20 25 30
 Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr
 35 40

<210> 4
<211> 44
<212> PRT
<213> Bos taurus

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 4
Ala Asn Gly Phe Leu Xaa Xaa Leu Arg Pro Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Arg Xaa Xaa Leu Cys Ser Phe Xaa Xaa Ala His Xaa Ile Phe Arg
 20 25 30
 Asn Xaa Xaa Arg Thr Arg Gln Phe Trp Val Ser Tyr
 35 40

<210> 5
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 5
Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Gln Gly Asn Leu Xaa Arg
 1 5 10 15
 Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Arg Xaa Val Phe
 20 25 30
 Xaa Asn Thr Xaa Arg Thr Thr Xaa Phe Trp Lys Gln Tyr
 35 40 45

<210> 6
<211> 46
<212> PRT
<213> Bos taurus

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 6
Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Gln Gly Asn Leu Xaa Arg
 1 5 10 15
 Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Arg Xaa Val Phe
 20 25 30
 Xaa Asn Thr Xaa Lys Arg Thr Thr Xaa Phe Trp Lys Gln Tyr
 35 40 45

<210> 7
<211> 36
<212> DNA
<213> Artificial Sequence

<220>

<223> Protein C mutagenic oligonucleotide
<400> 7
aaattaatac gactcaat agggagaccc aagctt

36

<210> 8
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Protein C mutagenic oligonucleotide

<400> 8
gcactccccgc tccaggctgc tgggacggag ctcctccagg aa
<210> 9
<211> 36
<212> DNA
<213> Artificial Sequence

42

<220>
<223> Protein C mutagenic oligonucleotide

<400> 9
acgctccacg ttgccgtgcc gcagctcctc taggaa
<210> 10
<211> 36
<212> DNA
<213> Artificial Sequence

36

<220>
<223> Protein C mutagenic oligonucleotide

<400> 10
ttccttagagg agctgcggca cggcaacgtg gagcgt

36

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Protein C mutagenic oligonucleotide

<400> 11
gcatttaggt gacactatacg aatagggccc tctaga

36

<210> 12
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Protein C mutagenic oligonucleotide

<400> 12
gaaggccatt gtgtcttccg tgtcttcgaa aatctcccgaa gc

42

<210> 13
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Protein C mutagenic oligonucleotide

<400> 13
 cagtgtgtca tccacatctt cgaaaatttc ctggc 36
 <210> 14
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Protein C mutagenic oligonucleotide

 <400> 14
 gccaaggaaa ttttcgaaga tgtggatgac acactg 36
 <210> 15
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Protein C mutagenic oligonucleotide

 <400> 15
 cagtgtgtca tccacatttt cgaaaatttc ctggc 36
 <210> 16
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Protein C mutagenic oligonucleotide

 <400> 16
 gccaaggaaa ttttcgaaaaa tgtggatgac acactg 36
 <210> 17
 <211> 45
 <212> PRT
 <213> Bos taurus

 <220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

 <400> 17
 Ala Asn Lys Gly Phe Leu Xaa Xaa Val Arg Lys Gly Asn Leu Xaa Arg
 1 5 10 15
 Xaa Cys Leu Xaa Xaa Pro Cys Ser Arg Xaa Xaa Ala Phe Xaa Ala Leu
 20 25 30
 Xaa Ser Leu Ser Ala Thr Asp Ala Phe Trp Ala Lys Tyr
 35 40 45

 <210> 18
 <211> 44
 <212> PRT
 <213> Bos taurus

 <220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

 <400> 18
 Ala Asn Ser Phe Leu Xaa Xaa Val Lys Gln Gly Asn Leu Xaa Arg Xaa
 1 5 10 15

Cys Leu Xaa Xaa Ala Cys Ser Leu Xaa Xaa Ala Arg Xaa Val Phe Xaa
 20 25 30
 Asp Ala Xaa Gln Thr Asp Xaa Phe Trp Ser Lys Tyr
 35 40

<210> 19
 <211> 44
 <212> PRT
 <213> Homo sapiens
 . . .
 <220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 19
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg His Ser Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 20
 <211> 44
 <212> PRT
 <213> Homo sapiens
 . . .
 <220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 20
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Gln Ser Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 21
 <211> 44
 <212> PRT
 <213> Homo sapiens
 . . .
 <220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 21
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Glu Ser Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 22
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 22
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Asp Ser Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 23
 <211> 44
 <212> PRT
 <213> Bos taurus

<220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 23
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg His Gly Asn Val Xaa Arg Xaa
 1 5 10 15
 Cys Ser Xaa Xaa Val Cys Xaa Phe Xaa Xaa Ala Arg Xaa Ile Phe Gln
 20 25 30
 Asn Thr Xaa Asp Thr Met Ala Phe Trp Ser Phe Tyr
 35 40

<210> 24
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 24
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Gln Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
 Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 25
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MOD_RES
 <222> (0)...(0)
 <223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 25
 Ala Asn Ser Phe Leu Xaa Xaa Leu Arg His Ser Ser Leu Xaa Arg Xaa
 1 5 10 15

Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Phe Xaa Ile Phe Glu
 20 25 30
 Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
 35 40

<210> 26
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 26
Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Glu Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Arg Xaa Ile Phe Lys
 20 25 30
Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr
 35 40

<210> 27
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 27
Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Asp Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Arg Xaa Ile Phe Lys
 20 25 30
Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr
 35 40

<210> 28
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 28
Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Pro Gly Ser Leu Xaa Arg Xaa
 1 5 10 15
Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Phe Xaa Ile Phe Lys
 20 25 30
Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr
 35 40

<210> 29
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 29

Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Pro Gly Ser Leu Xaa Arg Xaa				
1	5	10	15	
Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Arg Xaa Ile Phe Asp				
20	25		30	
Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr				
35	40			

<210> 30

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 30

Ala Asn Ala Phe Leu Xaa Xaa Leu Arg Gln Gly Ser Leu Xaa Arg Xaa				
1	5	10	15	
Cys Lys Xaa Xaa Gln Cys Ser Phe Xaa Xaa Ala Arg Xaa Ile Phe Glu				
20	25		30	
Asp Ala Xaa Arg Thr Lys Leu Phe Trp Ile Ser Tyr				
35	40			

<210> 31

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 31

Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Asp Gly Asn Leu Xaa Arg				
1	5	10	15	
Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Arg Xaa Val Phe				
20	25		30	
Xaa Asn Thr Xaa Arg Thr Thr Xaa Phe Trp Lys Gln Tyr				
35	40		45	

<210> 32

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (0)...(0)

<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 32

Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Glu Gly Asn Leu Xaa Arg				
1	5	10	15	
Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Arg Xaa Val Phe				
20	25		30	
Xaa Asn Thr Xaa Arg Thr Thr Xaa Phe Trp Lys Gln Tyr				
35	40		45	

<210> 33

<211> 45

<212> PRT

<213> Homo sapiens
<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid
<400> 33
Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Gln Gly Asn Leu Xaa Arg
1 5 10 15
Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Phe Xaa Val Phe
20 25 30
Xaa Asn Thr Xaa Arg Thr Thr Xaa Phe Trp Lys Gln Tyr
35 40 45

<210> 34
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid
<400> 34
Tyr Asn Ser Gly Lys Leu Xaa Xaa Phe Val Gln Gly Asn Leu Xaa Arg
1 5 10 15
Xaa Cys Met Xaa Xaa Lys Cys Ser Phe Xaa Xaa Ala Arg Xaa Val Phe
20 25 30
Xaa Asp Thr Xaa Arg Thr Thr Xaa Phe Trp Lys Gln Tyr
35 40 45

<210> 35
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (0)...(0)
<223> Xaa=gamma carboxyglutamic acid or glutamic acid

<400> 35
Ala Asn Ser Phe Leu Xaa Xaa Leu Arg Glu Gly Ser Leu Xaa Arg Xaa
1 5 10 15
Cys Ile Xaa Xaa Ile Cys Asp Phe Xaa Xaa Ala Lys Xaa Ile Phe Glu
20 25 30
Asp Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His
35 40

INTERNATIONAL SEARCH REPORT

Int'l application No
PCT/US 98/22152

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/55 C12N15/85 C12N9/64 C12N5/10 A61K38/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZHANG, LI ET AL: "The contributions of individual gamma-carboxyglutamic acid residues in th calcium -dependent binding of recombinant human protein C to acidic phospholipid vesicles." JOURNAL OF BIOLOGICAL CHEMISTRY, (1993) VOL. 268, NO. 16, PP. 12040-12045 ISSN: 0021-9258., XP002092838 see esp. p.12044 l. col, 1. par. ---	1,2,5, 15-17
A	ZHANG L ET AL: "ROLE OF INDIVIDUAL GAMMA CARBOXYGLUTAMIC ACID RESIDUES OF ACTIVATED HUMAN PROTEIN C IN DEFINING ITS IN-VITRO ANTICOAGULANT ACTIVITY." BLOOD, (1992) 80 (4), 942-952. CODEN: BLOOAW. ISSN: 0006-4971., XP002092839 see esp. p.948, r. col., 2. par. --- -/--	1-23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

10 February 1999

Date of mailing of the international search report

24/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/22152

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MCDONALD J F ET AL: "Comparison of naturally occurring vitamin K - dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site." BIOCHEMISTRY, (1997 APR 29) 36 (17) 5120-7. JOURNAL CODE: A0G. ISSN: 0006-2960., XP002092840 United States cited in the application see the whole document	1-23
A	FREEDMAN S. ET AL.: "Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 27, 5 July 1996, pages 16227-16236, XP002092841 see the whole document	1-23
A	RATCLIFFE J. ET AL.: "The importance of specific γ -carboxyglutamic acid residues in prothrombin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 32, 15 January 1993, pages 24339-24345, XP002092842 see the whole document	1-23
A	PERSSON E. AND NIELSEN L.: "Site-directed mutagenesis but not γ -carboxylation of Glu-35 in factor VIIa affects the association with tissue factor" FEBS LETTERS, vol. 385, no. 3, 6 May 1996, pages 241-243, XP002092843 cited in the application see the whole document	1-23
P,X	SHEN L ET AL: "Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10." BIOCHEMISTRY, (1997 DEC 23) 36 (51) 16025-31. JOURNAL CODE: A0G. ISSN: 0006-2960., XP002092844 United States see the whole document	1-23
2		

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/22152

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 22.23

is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 98/22152

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SHAH A. ET AL.: "Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII" PNAS, U.S.A., vol. 95, no. 8, 14 April 1998, pages 4229-4234, XP002092845 see the whole document -----	1-23